To conclude, the results for immune checkpoint inhibitor in NSCLC are encouraging, however, a multitude of questions related to predictive biomarkers to anti-PD-1/anti-PD-L1 therapies remains unanswered. This evidence concerns the gene CD274 and non-small cell lung carcinoma.